UNSPSC 51124405: Metildigoxin

This classification denotes an anti-arrhythmia agent, cardiotonic agent, and enzyme inhibitor with the molecular formula C42H66O14, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) I7GG1YUC5V, chemically known as digoxin, 4-o-methyl- but more generally known as metildigoxin, which bears US NIH Compound Identifier 35418. European Medicines Agency schedules Metildigoxin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08887MIG.

UNSPSC 51124405 Metildigoxin is a Commodity code representing specific pharmaceutical products procured by state and local health care and emergency services agencies. State and local governments buy injectable cardiac and emergency medications under this code—including metildigoxin alongside related advanced life support agents like epinephrine, adenosine, diltiazem, and labetalol—for use in emergency medical services, hospital systems, and public health programs. Issuing bodies include municipal fire and rescue departments (Tampa Fire Rescue), state health and human services agencies (Texas Health and Human Services Commission), and cooperative purchasing alliances serving multiple states and localities (Minnesota Multistate Cooperative Purchasing Alliance). The code reflects procurement of FDA-compliant, manufacturer-sourced pharmaceuticals with strict expiration-date requirements (typically nine months to one year minimum shelf life), compliance with cGMP and the Drug Supply Chain Security Act, and delivery through authorized pharmaceutical wholesalers. Vendors must maintain appropriate licensing, insurance, and Safety Data Sheets compliant with OSHA standards.

Recent activity spans multiple states and procurement models. The City of Tampa's Purchasing Department issued an IFB (Solicitation 26P00188) in April 2026 for Advanced Life Support Medications, with a response deadline of April 8, 2026 and an estimated contract value of $40,000, targeting a one-year term with renewal options and a 5 percent Small Local Business Enterprise bid discount. The Texas Health and Human Services Commission posted an RFI (HHS0017013) in April 2026 to gather vendor capabilities for direct-to-manufacturer prescription fulfillment outside traditional pharmacy benefit manager and group purchasing organization channels, with no award value identified in the preliminary information-gathering phase. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued an RFP (S1070000015802) due March 26, 2026 for generic multi-source pharmaceuticals and OTC products across participating state and local facilities in Minnesota and Oregon, with contract effectiveness set for July 1, 2026 and a two-year term, requiring vendor participation with at least two of three authorized wholesalers (AmerisourceBergen, Cardinal Health, Morris & Dickson) and a 3 percent administrative fee structure. Geographic activity includes Florida, Texas, Minnesota, and Oregon.